Krajina: Nový Zéland
Jazyk: angličtina
Zdroj: Medsafe (Medicines Safety Authority)
Clopidogrel bisulfate 97.875mg equivalent to clopidogrel 75 mg
Teva Pharma (New Zealand) Limited
Clopidogrel bisulfate 97.875 mg (equivalent to clopidogrel 75 mg)
75 mg
Film coated tablet
Active: Clopidogrel bisulfate 97.875mg equivalent to clopidogrel 75 mg Excipient: Colloidal silicon dioxide Dimeticone Hydrogenated castor oil Hyprolose Instacoat universal pink A05G30176 Lactose monohydrate
Blister pack, Al/Al cold formable, 28 tablets
Prescription
Prescription
Macleods Pharmaceuticals Limited
Prevention of vascular ischaemia associated with atherothrombotic events (MI, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.
Package - Contents - Shelf Life: Blister pack, Al/Al cold formable - 28 tablets - 36 months from date of manufacture stored at or below 25°C - Blister pack, Al/Al cold formable - 84 tablets - 36 months from date of manufacture stored at or below 25°C
2012-11-06
Version 1.2 1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME Arrow – Clopid 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains c lopidogrel hydrogen sulfate equivalent to clopidogrel 75 mg. Excipient with known effect: lactose For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Pink, circular, biconvex, film-coated tablet debossed “L 11” on one side of the tablet and plain on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prevention of vascular ischaemia associated with atherothrombotic events (MI, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. ACUTE CORONARY SYNDROME Arrow-Clopid is indicated in combination with aspirin for patients with: • Unstable angina or non-ST elevation MI. Arrow-Clopid is indicated for early and long-term reduction of atherothrombotic events (myocardial infarction, stroke, vascular death and refractory ischaemia) whether or not patients undergo cardiac revascularisation (surgical or PCI, with or without stent). • ST-segment elevation acute myocardial infarction. In this population, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re- infarction or stroke. 4.2 DOSE AND METHOD OF ADMINISTRATION DOSE ADULTS Generally, clopidogrel should be given as a single daily dose of 75 mg. In patients with acute coronary syndrome: • unstable angina or non-ST elevation myocardial infarction – clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued long-term at 75 mg once a day (with aspirin 75 mg-325 mg daily). • ST elevation acute myocardial infarction – clopidogrel treatment should be given as a single daily dose of 75 mg initiated with or without a 300 mg loading dose in combination with aspirin and with or without thrombolytics. SPECIAL POPULATIONS _Renal impairment _ Therapeutic experience is limited in patients with renal impairment. (see section 4.4 Special warnings and precautions Prečítajte si celý dokument